July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Association Between Aqueous VEGF Levels and Clinical Parameters in Ranibizumab Treatment for Eyes with Branch Retinal Vein Occlusion
Author Affiliations & Notes
  • Masahiro Miyake
    Ophthalmology, Kyoto University, Kyoto, Kyoto, Japan
  • Yuki Muraoka
    Ophthalmology, Kyoto University, Kyoto, Kyoto, Japan
  • Ayako Takahashi
    Ophthalmology, Kyoto University, Kyoto, Kyoto, Japan
  • Yuko Iida-Miwa
    Ophthalmology, Kyoto University, Kyoto, Kyoto, Japan
  • Tomoaki Murakami
    Ophthalmology, Kyoto University, Kyoto, Kyoto, Japan
  • Sotaro Ooto
    Ophthalmology, Kyoto University, Kyoto, Kyoto, Japan
  • Rima Ghashut
    Ophthalmology, Kyoto University, Kyoto, Kyoto, Japan
  • Kiyoshi Suzuma
    Ophthalmology, Kyoto University, Kyoto, Kyoto, Japan
  • Akitaka Tsujikawa
    Ophthalmology, Kyoto University, Kyoto, Kyoto, Japan
  • Yuto Iida
    Ophthalmology, Kyoto University, Kyoto, Kyoto, Japan
  • Footnotes
    Commercial Relationships   Masahiro Miyake, Novartis Pharma K.K (F); Yuki Muraoka, Bayer AG (R), Novartis Pharma K.K. (R), Santen (R); Ayako Takahashi, Novartis Pharma K.K (F); Yuko Iida-Miwa, Novartis Pharma K.K (F); Tomoaki Murakami, Bayer (R), Novartis Pharma K.K. (F), Novartis Pharma K.K. (R), Santen (R); Sotaro Ooto, Bayer AG (R), Novartis Pharma K.K. (R), Santen (R); Rima Ghashut, Novartis Pharma K.K (F); Kiyoshi Suzuma, Bayer AG (F), Bayer AG (R), Novartis Pharma K.K. (F), Novartis Pharma K.K. (R), Santen (F), Santen (R); Akitaka Tsujikawa, Bayer AG (F), Bayer AG (R), Novartis Pharma K.K. (F), Novartis Pharma K.K. (R), Santen (F), Santen (R); Yuto Iida, Novartis Pharma K.K (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4280. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Masahiro Miyake, Yuki Muraoka, Ayako Takahashi, Yuko Iida-Miwa, Tomoaki Murakami, Sotaro Ooto, Rima Ghashut, Kiyoshi Suzuma, Akitaka Tsujikawa, Yuto Iida; Association Between Aqueous VEGF Levels and Clinical Parameters in Ranibizumab Treatment for Eyes with Branch Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4280.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate aqueous vascular endothelial growth factor (VEGF) levels and their association with clinical parameters of eyes with branch retinal vein occlusion (BRVO) that received intravitreal ranibizumab (IVR) injections for macular edema (ME).

Methods : This prospective study was approved by the Institutional Review Board, Kyoto University Graduate School of Medicine (Kyoto, Japan), and adhered to the Declaration of Helsinki. Forty-one consecutive eyes (41 patients; mean age, 73.0±10.8 years) with treatment-naïve, acute BRVO accompanying ME were included. All patients received 3 monthly IVR injections. Each patient was examined monthly for 12 months after the initial injection, and an additional IVR injection was administered when ME or serous retinal detachment was evident at the fovea on optical coherence tomography (OCT). Except ranibizumab, these eyes received no other treatment, such as scatter laser photocoagulation, grid laser photocoagulation, steroid treatment, surgical intervention, or other anti-VEGF agents. VEGF levels were measured using an enzyme-linked immunosorbent assay with aqueous humor that was obtained immediately before the initial IVR injection. The total retinal nonperfusion area (NPA) and vascular leakage of the retina, central foveal thickness (CFT), and macular NPA were quantitively measured with ultrawide-field fluorescein angiography, OCT, and OCT angiography, respectively.

Results : The mean aqueous VEGF level before the initial IVR injection was 279.0±162.0 pg/ml, which was significantly associated with the total NPA, dye leakage, CFT, and height of serous retinal detachment at the fovea (r=0.547, P<0.001; r=0.775, P<0.001; r=0.465, P=0.002; r=0.548, P<0.001, respectively). VEGF levels in eyes with broad NPA varied based on the amount of vascular leakage. The aqueous VEGF levels did not significantly associate with initial and final visual acuities (VAs), initial macular NPAs (superficial and deep capillary plexuses), or the number of IVR injections over 12 months (P=0.228, P=0.779, P=0.051, P=0.082, P=0.934, respectively).

Conclusions : Aqueous VEGF levels in eyes with treatment-naïve BRVO were significantly associated with vascular leakage and total NPA that were examined before the initial IVR injection. However, pretreatment VEGF levels were not a prognostic factor for final VA and the number of IVR injections required.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×